Recent Updates
Recently added Catalysts
BMRN Positive Sentiment Score: 70/100

BioMarin to Participate in Bank of America 2023 Health Care Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will...

Key Takeaway: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced its participation in the Bank of America 2023 Health Care Conference. Brian Mueller, the company's Chief Financial Officer, will present on May 10, 2023, at 3:40 PM PT in Las Vegas, NV. An audio webcast of his presentation will be available live, with an archived version accessible on the company's website afterward. This event highlights BioMarin's commitment to transparency and investor relations.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin will participate in a prominent health care conference.
  • The company's leadership is engaging with investors.
  • BioMarin's historical success in developing therapies for rare genetic disorders.

Full Press Release Details

SAN RAFAEL, Calif. , May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Brian Mueller , Executive Vice President, Chief Financial Officer of BioMarin will present at the Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:40pm PT , in Las Vegas , NV.
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com .
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 650) 374-2803
SOURCE BioMarin Pharmaceutical Inc.

21 %

Frequently Asked Questions

When will BioMarin present at the Bank of America conference?

BioMarin will present on May 10, 2023, at 3:40 PM PT.

How can I access the presentation's audio webcast?

The audio webcast can be accessed live at BioMarin's investor website.

What does BioMarin focus on in terms of therapies?

BioMarin develops therapies targeting the root causes of genetic conditions.

When was BioMarin founded?

BioMarin was founded in 1997.

How many commercial therapies has BioMarin created?

BioMarin has developed eight transformational commercial therapies.

Last updated: May 4, 2023